Study Design
The study included 64 patients who underwent radical prostatectomy after primary staging with mpMRI and 68Ga-PSMA PET/MRI, between 2017 and 2019. Clinical (age, total prostate-specific antigen [PSA], type of operation), radiological (length, volume, PI-RADS score, maximum standardised uptake value [SUVmax] of lesions, prostate volume), and pathological (biopsy and prostatectomy International Society of Urological Pathology [ISUP] grade, pathological tumour stage, pathological tumour and prostate volumes) data were recorded. Prostate-specific antigen density (PSAD) was calculated by dividing the total PSA by the prostate volume. Patients who received neoadjuvant therapy, whose imaging tests were performed at a different centre, or who had another known history of malignancy were excluded from the study.